Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
FDC.NS
BuyPremium GrowerFDC Limited · Healthcare · India · $594M · Avg Vol: $924K/d
77
StockRankGet insider-trade alerts
Q
76
V
44
M
53
P/E (TTM)
19.7x
ROE
11.3%
D/E
0.0x
Dividend %
1.4%
COMPANY DESCRIPTION
FDC Limited, together with its subsidiaries, manufactures and trades in pharmaceutical products in India, the United States, and internationally.
FINANCIAL SUMMARY (INR)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 17.8B | 19.4B | 21.0B | 21.6B | 6.8% | 22.0B |
| EPS (INR) | 11.67 | 18.58 | 16.39 | 17.29 | 14.0% | 18.05 |
| Shares | 165.9M | 162.8M | 162.8M | 162.8M | -1.9% | 162.8M |
| Debt | 283.2M | 205.2M | 211.7M | 154.7M | -18.3% | 155.2M |
| Equity | 19.8B | 21.0B | 22.8B | 24.9B | 7.8% | — |
| Op CF | 1.5B | 2.2B | 3.2B | 2.0B | 9.0% | 2.0B |
| Inv CF | 111.3M | -170.8M | -2.0B | -1.1B | — | — |
| Fin CF | -1.8B | -2.0B | -921.2M | -933.3M | — | — |
Loading 1Y...
PRICE (1Y)-14.5%
SMA 50SMA 200
Close
$3.71
RSI (14)
59.6
52W High
$5.46
From 52W High
0.7%
SCORE BREAKDOWN
Quality
76
ROIC
15.4%84.0
ROE
11.3%74.0
GP/Assets
50.5%86.9
Op. Margin
19.2%81.8
FCF/Assets
0.5%47.4
Piotroski
668.8
Int. Cover
50.0x89.2
D/E Ratio
0.01x87.6
Current Ratio
3.11x56.9
Value
44
P/E (TTM)
19.7x60.4
EV/EBITDA
14.5x49.5
P/FCF
406.8x4.0
P/B
2.3x56.2
P/S
2.6x60.9
Div Yield
1.4%39.4
Momentum
53
52W High %
68%46.7
RS 6M
-1%64.9
SMA 50/200
1.01x58.8
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+30%41.8
Q Growth
9%46.9
FUNDAMENTALS
Market Cap
$594M
P/E (Forward)
15.2x
Gross Margin
67.3%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of FDC.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| FDC.NS | FDC Limited(you) | $594M | 77 | Buy |
| INNOVACAP.NS | Innova Captab Limited | $707M | 79 | Buy |
| RPGLIFE.NS | RPG Life Sciences Limited | $489M | 79 | Buy |
| MOREPENLAB.NS | Morepen Laboratories Limited | $677M | 85 | Strong Buy |
| GUFICBIO.NS | Gufic Biosciences Limited | $466M | 70 | Buy |
| AARTIDRUGS.NS | Aarti Drugs Limited | $406M | 82 | Strong Buy |
| INDSWFTLAB.NS | Ind-Swift Laboratories Limited | $356M | 80 | Strong Buy |
| IOLCP.NS | IOL Chemicals and Pharmaceuticals Limited | $653M | 89 | Strong Buy |
| SOLARA.NS | Solara Active Pharma Sciences Limited | $357M | 81 | Strong Buy |
| HIKAL.NS | Hikal Limited | $320M | 74 | Buy |
Peer medians: ROE 11.9% · P/E 42.8x · Gross margin 59.4%